Lack of improvement in the treatment of hyperlipidemia among patients with type 2 diabetes

American Journal of Medicine

Volumn 114, Issue 5, 2003, Pages 377-382

  Mehler, Philip S ^a,b,c   Esler, Anne ^b,c   Estacio, Raymond O ^a,b,c   MacKenzie, Thomas D ^a,b,c   Hiatt, William R ^b,c   Schrier, Robert W ^b  

^a DENVER HEALTH AND HOSPITAL AUTHORITY   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c Colorado Prevention Center ^*  (United States)

Author keywords

Diabetes; Goals; Hyperlipidemia; Treatment; Trends

Indexed keywords

ANTILIPEMIC AGENT; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NISOLDIPINE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIET RESTRICTION; FEMALE; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH; TREATMENT OUTCOME;

EID: 0242669230     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(02)01566-8     Document Type: Article

References (36)

1. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesteremia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 333:1995;1301-1307.
2. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389.
3. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Circulation. 81:1994;1329-1445.
4. Nieto F.J., Alonso J., Chambless L.E., et al. Population awareness and control of hypertension and hypercholesteremia. Arch Intern Med. 155:1995;677-684.
5. Steiner G. Lipid intervention trials in diabetes. Diabetes Care. 23:2000;B49-B53.
6. Mietten H., Lehto S., Salomaa V., et al. Impact of diabetes on mortality after the first myocardial infarction: the FINMONICA Myocardial Infarction Register Study Group. Diabetes Care. 21:1998;69-75.
7. Haffner S.M., Lehto S., Ronnemaa T., et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 339:1998;229-234.
8. Moss S.E., Klein R., Klein B.E. Cause-specific mortality in a population-based study of diabetes. Am J Public Health. 81:1991;1158-1162.
9. Burke J.P., Williams K., Gaskill S.P., et al. Rapid rise in the incidence of type 2 diabetes from 1987-1996. Results from the San Antonio Heart Study. Arch Intern Med. 159:1999;1450-1456.
10. Savage S., Johnson N., Estacio R., et al. The ABCD trial. Rationale and design of a trial of hypertension control (moderate or intensive) in type II diabetes. Online J Curr Clin Trials. Nov. 24:1993;104. Doc No.
11. Estacio R.O., Gifford N., Jeffers B.W., Schrier R.W. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care. 23:2000;B54-B64.
12. McCulloch D.K., Glasgow R.E., Hampson S.E., Wagner E. A systematic approach to diabetes management in the post-DCCT era. Diabetes Care. 17:1994;765-769.
13. Burt V.L., Whelton P., Roccella E.J., et al. Prevalence of hypertension in the US adult population: results from the third National Health And Nutrition Examination Survey 1988-1991. Hypertension. 25:1995;305-313.
14. Burt V.L., Cutler J.A., Higgins, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult U.S. population. Data from the health examination surveys, 1960 to 1991. Hypertension. 26:1995;60-69.
15. Berlowitz D.R., Ash A.S., Hickey E.C., et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 339:1998;1957-1963.
16. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction. Lancet. 2:1988;349-360.
17. Randomized trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction - ISIS-I. Lancet. 2:1986;57-66.
18. McCormick D., Gurwitz J.H., Lessard D., et al. Use of aspirin, beta-blockers and lipid-lowering medications before recurrent acute myocardial infarction: missed opportunities for prevention? Arch Intern Med. 159:1999;561-567.
19. Pyorala K., Pedersen T.R., Kjekshus J., et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 20:1997;614-620.
20. Grant R.W., Cagliero E., Murphy-Sheehy P., Singer D.E., Nathan D.M., Meigs J.B. Comparison of hyperglycemia, hypertension, and hypercholesterolemia management in patients with type 2 diabetes. Am J Med. 112:2002;603-609.
21. Caixas A., Ordonez-Lanos J., De Leiva A., et al. Optimization of glycemic controls by insulin therapy decreases the proportion of small dense LDL particles in diabetic patients. Diabetes. 46:1997;1207-1213.
22. Weiner J.P., Parente S.T., Garnick D.W., et al. Variation in office-based quality. A claims-based profile of care provided to Medicare patients with diabetes. JAMA. 273:1995;1503-1508.
23. Harris M.I., Eastman R.C., Cowie C.C., et al. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care. 22:1999;403-408.
24. Larme A.C., Pugh J.A. Attitudes of primary care providers towards diabetes: barriers to guideline implementations. Diabetes Care. 21:1998;1391-1396.
25. Avorn J., Monette A.J., Lalcour A., et al. Persistence of use of lipid-lowering medications: a cross national study. JAMA. 279:1998;1458-1462.
26. McBridel P., Schrott H.G., Plane M.D., et al. Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease. Arch Intern Med. 159:1998;1238-1244.
27. Yarzebski J., Bujor C.F., Goldberg R.J., et al. A community-wide survey of physician practices and attitudes toward cholesterol management in patients with recent acute myocardial infarction. Arch Intern Med. 162:2002;797-804.
28. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497.
29. Meigs J.B., Singer D.E., Sullivan L.M., et al. Metabolic control and prevalent cardiovascular disease in non-insulin dependent diabetes mellitus (NIDDM): the NIDDM Patient Outcome Research Team. Am J Med. 102:1997;38-47.
30. Grimshaw J.M., Russell I.T. Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations. Lancet. 342:1993;1317-1322.
31. Phillips L., Branch W.T., Cook C.B., et al. Clinical inertia. Ann Intern Med. 135:2001;825-834.
32. Harris D.E., Reord N.B., Gipson G.W., Pearson T.A. Lipid lowering in a multidisciplinary clinic compared with primary physician management. Am J Cardiol. 81:1998;929-933.
33. Larme A.C., Pugh J.A. Attitudes of primary care providers towards diabetes: barriers to guideline implementation. Diabetes Care. 21:1998;1391-1396.
34. Shaffer J., Wexler L.F. Reducing low-density lipoprotein cholesterol levels in an ambulatory care system. Results of a multidisciplinary collaborative practice lipid clinic compared with traditional physician-based care. Arch Intern Med. 155:1995;2330-2335.
35. Tight blood pressure control and risks of macrovascular disease and microvascular complications in type 2 diabetes. BMJ. 317:1998;703-713.
36. Management of dyslipidemia in adults with diabetes. Position statement. Diabetes Care. 25:(suppl 1):2002;33-49.